Our client is a stealth startup committed to bringing the next generation of pharmaceutical treatments to combat cancer.Job Title: Fractional Chief Scientific Officer / Chief Medical Officer (Hybrid Role)Location: Remote / HybridTime Commitment: Part-time / FractionalAbout the Opportunity:
We are partnering with a stealth-mode, preclinical-stage biotechnology company advancing a first-in-class, small-molecule oncology therapeutic platform derived from a proprietary natural-compound chemical library.
With compelling in-vivo tumor eradication data and broad anti-tumor activity across multiple cancer models, the company is poised to move its lead candidate toward IND and first-in-human (FIH) studies.
They are seeking a fractional CSO/CMO hybrid who can provide strategic and hands-on leadership across preclinical development, translational planning, IND readiness, and early clinical design.
Key Responsibilities:
Lead the scientific and medical strategy from late-stage preclinical through IND-enabling studies and into FIH trial planning.
Guide mechanism-of-action studies, pharmacology, toxicology, and dose rationale in collaboration with discovery and translational teams.
Oversee CROs responsible for IND-enabling studies and ensure alignment with regulatory and clinical objectives.
Contribute to target product profile, clinical development plan, and biomarker strategy.
Work closely with company leadership on pipeline prioritization, scientific positioning, and external communications (including investors and potential partners).
Support preparation of regulatory documents and attend meetings with external stakeholders, as needed.?
Qualifications:
MD required; oncology or related translational science background preferred.
15+ years of experience in biotech/pharma, including roles with CSO, CMO, or VP-level responsibility.
Recent experience in small company (under 10).
Strong track record leading oncology programs from preclinical through IND and FIH studies.
Deep understanding of tumor biology, solid and hematologic malignancies, and translational strategy.
Demonstrated experience managing CROs and external scientific vendors in a resource-constrained, fast-paced environment.
Prior experience in early-stage biotech; comfortable operating in a lean, hands-on leadership role.
Why This Role?
Opportunity to drive a highly differentiated oncology therapeutic forward from discovery to clinic.
Strategic leadership role in a mission-driven, agile organization.
Flexible, fractional engagement designed for high-impact contributors.
